Effect of probiotics on Campylobacter colonisation within the broiler gut

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-06d290-2026-07-23T20:17:06+01:00",
    "date": "2026-07-23T20:17:06+01:00",
    "ocid": "ocds-h6vhtk-06d290",
    "initiationType": "tender",
    "planning": {
        "documents": [
            {
                "id": "069976-2026",
                "documentType": "plannedProcurementNotice",
                "noticeType": "UK3",
                "description": "Planned procurement notice on Find a Tender",
                "url": "https://www.find-tender.service.gov.uk/Notice/069976-2026",
                "datePublished": "2026-07-23T20:17:06+01:00",
                "format": "text/html"
            }
        ]
    },
    "parties": [
        {
            "id": "GB-PPON-PJRM-6866-LYYX",
            "name": "Food Standards Agency",
            "identifier": {
                "scheme": "GB-PPON",
                "id": "PJRM-6866-LYYX"
            },
            "address": {
                "streetAddress": "YO1 7PR",
                "locality": "York",
                "postalCode": "YO1 7PR",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKE21"
            },
            "contactPoint": {
                "name": "FSA Commercial",
                "email": "fsa.commercial@food.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.food.gov.uk/",
                "classifications": [
                    {
                        "id": "publicAuthorityCentralGovernment",
                        "scheme": "UK_CA_TYPE",
                        "description": "Public authority - central government"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-PPON-PJRM-6866-LYYX",
        "name": "Food Standards Agency"
    },
    "tender": {
        "id": "C461206",
        "legalBasis": {
            "id": "2023/54",
            "scheme": "UKPGA",
            "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
        },
        "title": "Effect of probiotics on Campylobacter colonisation within the broiler gut",
        "description": "A key component of the FSA work is to reduce the burden of foodborne disease in the UK. Campylobacter is the leading bacterial cause of foodborne disease in the UK, with chicken meat being the most common food source of exposure to this pathogen. Campylobacter is widespread in chicken farms, with 60% of UK broilers flocks carrying the pathogen at the point they are slaughtered. Interventions further down the food chain do not reliably eliminate this pathogen. Therefore, reducing Campylobacter colonisation on broiler flocks and contamination on chicken meat is a priority area for the FSA as this will contribute towards reducing human exposure and subsequent reported cases of foodborne disease. A clear evidence gap remains on whether probiotics can consistently affect Campylobacter levels in broilers, across commercial UK farms under routine production conditions, and what magnitude of log reduction is realistically achievable. To address this evidence gap, the FSA are seeking research proposals for an innovative field-trial based study carried out in real-life intensive broiler houses to assess the effectiveness of a range of probiotics on reducing or delaying Campylobacter colonisation in the gut of broiler flocks. The research should be designed to answer the following questions: * \"To what extent can commercially available probiotic formulations reduce or delay Campylobacter colonisation in broiler flocks under commercial intensive housed farming conditions, and does this translate into reduced Campylobacter contamination of carcasses at processing?\" * \"What is the effect of these formulations on welfare and production performance indicators such as mortality, growth rate, feed conversion efficiency and flock health outcomes?\" We envisage that the proposed study design will consist of several discrete phases. Given the complexity of controlling Campylobacter in broiler flocks, we would like the inclusion of break clauses at the end of key deliverables to allow sufficient time for the FSA, together with the researcher team, to review the phase findings and determine whether there is sufficient evidence and justification to proceed to the next stage of the project. If not, then the FSA reserves the right to terminate the project.",
        "status": "planned",
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "73000000",
                        "description": "Research and development services and related consultancy services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "73110000",
                        "description": "Research services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "73111000",
                        "description": "Research laboratory services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "73100000",
                        "description": "Research and experimental development services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "85200000",
                        "description": "Veterinary services"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "value": {
            "amountGross": 600000,
            "amount": 500000,
            "currency": "GBP"
        },
        "procurementMethod": "open",
        "procurementMethodDetails": "Open procedure",
        "mainProcurementCategory": "services",
        "aboveThreshold": true,
        "coveredBy": [
            "GPA"
        ],
        "submissionMethodDetails": "Tenders for FSA funded projects must be submitted through the health-family single e-Commercial System (Atamis), using the following link: https://health-family.force.com/s/Welcome",
        "submissionTerms": {
            "electronicSubmissionPolicy": "allowed",
            "languages": [
                "en"
            ]
        },
        "tenderPeriod": {
            "endDate": "2026-10-13T12:00:00+01:00"
        },
        "enquiryPeriod": {
            "endDate": "2026-09-30T12:00:00+01:00"
        },
        "awardPeriod": {
            "endDate": "2026-11-16T23:59:59Z"
        },
        "lots": [
            {
                "id": "1",
                "status": "planned",
                "value": {
                    "amountGross": 600000,
                    "amount": 500000,
                    "currency": "GBP"
                },
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "quality",
                            "name": "Technical",
                            "description": "The extent to which the bidder demonstrates a clear understanding of the requirement and provides a robust, credible, and deliverable methodology. Responses will be evaluated against the quality of the proposed approach, technical capability, relevant experience, project management arrangements, risk management, resources, and ability to achieve the required outcomes and deliverables. Scoring methodology will be provided in the specification.",
                            "numbers": [
                                {
                                    "number": 80,
                                    "weight": "percentageExact"
                                }
                            ]
                        },
                        {
                            "type": "cost",
                            "name": "Commercial",
                            "description": "Commercial / Value for Money (20%) - Assessment of the bidder's proposed pricing and overall value for money. Evaluation will consider the transparency, reasonableness and competitiveness of costs, ensuring that the proposed solution delivers the required outcomes and quality standards while providing the best value for public funds. Scoring methodology will be provided in the specification",
                            "numbers": [
                                {
                                    "number": 20,
                                    "weight": "percentageExact"
                                }
                            ]
                        }
                    ]
                },
                "selectionCriteria": {
                    "criteria": [
                        {
                            "type": "economic",
                            "description": "Standard PSQ"
                        },
                        {
                            "type": "technical",
                            "description": "See Specification"
                        }
                    ]
                },
                "suitability": {
                    "sme": true,
                    "vcse": true
                },
                "contractPeriod": {
                    "startDate": "2027-01-01T00:00:00Z",
                    "endDate": "2028-12-31T23:59:59Z",
                    "maxExtentDate": "2029-12-31T23:59:59Z"
                },
                "hasRenewal": true,
                "renewal": {
                    "description": "optional 12 month extension option."
                },
                "hasOptions": true,
                "options": {
                    "description": "The contract will be awarded for an initial period of 24 months, commencing on 1 January 2027 and ending on 31 December 2028. The Authority reserves the right, at its sole discretion, to extend the contract for a further period of up to 12 months, subject to satisfactory supplier performance, continued business need, availability of funding, and any necessary approvals. Given the complexity of controlling Campylobacter in broiler flocks, the contract will also include break clauses linked to key project deliverables. These break points will provide the FSA and the research team with the opportunity to review findings from each phase of the project and determine whether there is sufficient evidence, justification and ongoing value for money to proceed to subsequent stages. The exercise of any extension option and continuation beyond agreed break points will be subject to the outcomes of these reviews."
                }
            }
        ],
        "communication": {
            "futureNoticeDate": "2026-09-01T23:59:59+01:00"
        },
        "contractTerms": {
            "financialTerms": "Payment of undisputed invoices will be made within 30 days of receipt of invoice, which must be submitted promptly by the Supplier. All invoices must be sent, quoting a valid Purchase Order Number (PO Number). Within 10 Working Days of receipt of your countersigned copy of this Order Form, we will send you a unique PO Number. You must be in receipt of a valid PO Number before submitting an invoice. To avoid delay in payment it is important that the invoice is compliant and that it includes a valid PO Number, item number (if applicable) and the details (name, email, and telephone number) of your Buyer contact (i.e. Buyer Authorised Repre-sentative). Non-compliant invoices may be sent back to you, which may lead to a delay in payment."
        },
        "riskDetails": "Risks associated with a scientific services project of this nature may include, but are not limited to, delays in project delivery, budgetary pressures, changes in scope or requirements, difficulties in obtaining representative samples, sampling plan amendments, sample quality or availability issues, laboratory capacity constraints, analytical method development and validation challenges, equipment failure, data quality concerns, regulatory or legislative changes, stakeholder availability, and delays in the provision of information, materials or approvals. Additional risks may include difficulties securing access to farms, animals, facilities or study sites; disease outbreaks or biosecurity restrictions impacting sampling activities; seasonal or environmental factors affecting sample collection; staff turnover or loss of key personnel; subcontractor performance issues; supply chain disruptions affecting equipment, consumables or laboratory reagents; ethical or governance approval delays; data management, storage or information security issues; and challenges in reproducing or validating scientific findings. Given the phased nature of the project, there is also a risk that the findings, evidence generated or outcomes achieved during an individual phase may not provide sufficient scientific justification, value for money, or confidence to progress to subsequent phases. Break points will therefore be included at the completion of key deliverables to enable the Authority and the research team to review progress, assess findings and determine whether continuation to the next phase remains appropriate. There is also a risk that research findings or analytical results may not generate the expected outcomes, requiring additional investigation, testing, refinement of methodologies or revisions to the proposed approach. Suppliers will be expected to identify, manage and mitigate such risks throughout the contract lifecycle to ensure delivery of the agreed objectives, timelines and outputs while maintaining scientific quality and robustness."
    },
    "language": "en"
}